Friday, November 13, 2026

Invesco Mortgage Capital faces $5.4B repo rollover risk as market conditions tighten

Invesco Mortgage Capital Inc. carries $5.4 billion in repurchase agreement borrowings that require continuous refinancing. The mortgage REIT faces catastrophic risk if repo lenders withdraw funding or increase haircut requirements. Asset liquidation at depressed prices could result if the company cannot roll over short-term debt.

Invesco Mortgage Capital faces $5.4B repo rollover risk as market conditions tighten
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Invesco Mortgage Capital Inc. relies on $5.4 billion in repurchase agreement borrowings to finance its mortgage-backed securities portfolio. The short-term funding structure creates continuous rollover exposure for the mortgage REIT.

Repo markets provide daily financing for agency and non-agency MBS holdings. Lenders can withdraw liquidity or demand higher collateral margins during market stress. The Federal Reserve's quantitative tightening has reduced repo market capacity by $95 billion monthly through Treasury and MBS runoff.

Haircut increases force immediate collateral posting. A 5-point haircut jump on $5.4 billion in borrowings requires $270 million in cash or asset sales. Mortgage REITs typically operate with 7:1 to 10:1 leverage ratios, leaving minimal buffer for margin calls.

The March 2020 repo crisis demonstrated this vulnerability. Agency MBS spreads widened 120 basis points in two weeks as lenders pulled back. Several mortgage REITs faced margin calls exceeding $1 billion, forcing emergency asset sales at 15-20% discounts to pre-crisis prices.

Invesco Mortgage Capital holds residential and commercial mortgage-backed securities across agency and non-agency categories. Agency MBS typically receive lower repo haircuts due to government backing, but non-agency CMBS and credit-sensitive assets face haircuts of 10-25% in normal conditions.

Rising interest rates compound the rollover risk. The Fed's benchmark rate at 4.25-4.50% has increased repo borrowing costs by 425 basis points since March 2022. Net interest margins compress when asset yields lag funding cost increases.

Book value erosion accompanies forced liquidations. Mortgage REITs mark portfolios to market quarterly. Selling securities below carrying value crystallizes paper losses and reduces equity capital available to support remaining leverage.

Repo counterparty concentration adds risk. Major dealers include JPMorgan, Bank of America, and Barclays. A single lender reducing credit lines can trigger liquidity stress requiring rapid portfolio adjustments.

Credit-sensitive MBS face wider liquidation discounts than agency securities. Non-agency RMBS and CMBS lack government guarantees, creating 25-40% bid-ask spreads during distressed selling periods.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com